The American College of Physicians (ACP) developed this clinical guideline to update recommendations on newer pharmacologic treatments of type 2 diabetes. This clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients’ values...
Levin, Adeera;
Ahmed, Sofia B;
Carrero, Juan Jesus;
Foster, Bethany;
Francis, Anna;
Hall, Rasheeda K;
Herrington, Will G;
Hill, Guy;
Inker, Lesley A;
Kazancıoğlu, Rümeyza;
Lamb, Edmund;
Lin, Peter;
Madero, Magdalena;
McIntyre, Natasha;
Morrow, Kelly;
Roberts, Glenda;
Sabanayagam, Dharshana;
Schaeffner, Elke;
Shlipak, Michael;
Shroff, Rukshana;
Tangri, Navdeep;
Thanachayanont, Teerawat;
Ulasi, Ifeoma;
Wong, Germaine;
Yang, Chih-Wei;
Zhang, Luxia;
Robinson, Karen A;
Wilson, Lisa;
Wilson, Renee F;
Kasiske, Bertram L;
Cheung, Michael;
Earley, Amy;
Stevens, Paul E.
Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) updates the KDIGO 2012 guideline and has been developed with patient partners, clinicians, and researchers around the world, using robust methodology. This update, based on a su...
The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating people with diabetes and CKD. ...
Clinical question What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual care (lifestyle interventions and/or other diabetes drugs) in adults with type 2 diabetes at different risk for cardiovascular ...
